Thursday, July 9, 2026

pharma · severe uncontrolled asthma · mild to moderate asthma, Chronic Obstructive Pulmonary Disease (COPD) · GENB

Generate Biomedicines

Generate Biomedicines is a pharma organization headquartered in Somerville, USA. It trades on NYSE under ticker GENB. Primary therapeutic focus areas include severe uncontrolled asthma, mild to moderate asthma, Chronic O

Somerville, USA HQ
325 Employees
Public company Type
GENB · NYSE Ticker
Company details
Status
Public
HQ
Somerville, USA
Employees
325
Programs
8
Drugs
7
Patents
1
Clinical program

GB-0669

Phase 1 · small molecule · SARS CoV-2

GB-0669 for SARS CoV-2 is a Phase 1 program (small_molecule) at Generate Biomedicines with 1 ClinicalTrials.gov record(s).

← All Generate Biomedicines projects Phase 1 small molecule completed

Internal code GB-0669-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Generate Biomedicines
Phase
Phase 1
Modality
small_molecule
Indication
SARS CoV-2
Status
completed
Trials
1

Clinical trials